Biotechnology sector performed well on both public and private markets. Large public biotech stocks continued to climb while smaller stocks remained leveled. Private financing deal flow increased substantially, albeit leaving early stage start-ups behind. Biotech sector experienced an overall increase in VC activity during 2Q 2013 and after much less inspiring first quarter. The comeback of VC funding was consistent with strong public markets as well as high, 13, number of completed Life Sciences IPO transactions.
New Common Stock Valuation Guide – Are Valuations Going Up?
Not to be outdone by 2025’s public stock markets, private stock valuations are about to go up. We can thank the new draft AICPA guidance. A new approach to secondary transactions and liquidation preferences is likely to increase the valuations of some common stock.
February 18, 2026
